Mindray, CNE100003G67

Mindray stock gets CNY 166.00 target in October update

Published on 10/15/2026 at 10:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue reached CNY 17.747 billion, up 6.00 percent. The October update set a CNY 166.00 target for Mindray stock.

Growth and valuation signals

  • Futu reported a CNY 166.00 target for Mindray on October 13, 2026.
  • First-half 2026 revenue reached CNY 17.747 billion, up 6.00 percent.
  • Mindray stock was last at CNY 167.00 at 3:04 p.m. CST on October 15, 2026, on Shenzhen.
Mindray, CNE100003G67, Illustration mit AI erstellt.
Mindray, CNE100003G67, Illustration mit AI erstellt.

Mindray (ISIN CNE100003G67) was assigned a CNY 166.00 target in an October 13, 2026 market update carried by Futu. The target came with a Buy recommendation and puts the latest operating figures at the center of the valuation debate.

First-half growth was uneven

Futu reported that revenue reached CNY 17.747 billion in the first half of 2026, up 6.00 percent from the prior-year period. Net profit attributable to shareholders fell 5.37 percent to CNY 4.797 billion, while adjusted net profit declined 3.32 percent to CNY 4.785 billion.

The quarterly detail was more constructive. Second-quarter revenue rose 10.45 percent to CNY 9.395 billion, and net profit attributable to shareholders increased 1.10 percent to CNY 2.467 billion, according to the same September 30, 2026 report.

What does the target mean for growth?

The answer depends on the international business and newer product lines. Overseas revenue reached CNY 9.471 billion in the first half of 2026, up 13.67 percent, and represented 53 percent of total revenue, according to ChoZan. Emerging businesses generated CNY 3.110 billion, up 19.59 percent, while medical imaging revenue fell 5.78 percent.

The mixed profile explains why the target is tied to execution rather than a simple earnings rebound. International growth and emerging businesses are expanding, but domestic equipment demand and medical imaging remain uneven. ChoZan also reported that international M-Connect projects exceeded 1,000 signed deployments by June 30, 2026, adding a platform element to Mindray's equipment portfolio.

Three dated stock developments

On September 30, 2026, Futu carried Citic Securities' assessment alongside Mindray's CNY 17.747 billion first-half revenue. On October 12, 2026, ChoZan highlighted international revenue at 53 percent of the total and more than 1,000 M-Connect deployments. On October 13, 2026, Futu reported the CNY 166.00 target and Buy recommendation.

Next reporting date

The next scheduled reporting date is October 30, 2026, according to QuarterlyEarnings.info.

Shenzhen valuation context

Mindray was last at CNY 167.00 on the Shenzhen Stock Exchange on October 15, 2026 at 3:04 p.m. CST. The same quote showed a market capitalization of CNY 202.5 billion and a 52-week range of CNY 130.66 to CNY 233.95, giving the target debate a clearly defined market context.

Mindray key facts

  • Company: Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • ISIN: CNE100003G67
  • Ticker: 300760.SZ
  • Primary exchange: Shenzhen Stock Exchange
  • Market capitalization: CNY 202.5 billion (as of October 15, 2026)
  • 52-week range: CNY 130.66-CNY 233.95 (as of October 15, 2026)
  • Sector / Industry: Health Care / Medical Equipment and Supplies

Market context: Market report Shanghai Composite.

More news and analyses on Mindray stock

Disclaimer...

en | CNE100003G67 | MINDRAY | boerse | 70327044 | bgmi